Chief scientific officer Jonathan Gillis sold 69,835 shares across 5 transactions for $2,087,687.49 at blended average $29.89
Jonathan Gillis, holding a Chief Scientific Officer role (CAAO and PAO), executed 5 separate sales totaling 69,835 shares for $2,087,687.49 on April 27-28, 2026. The sales occurred across a narrow price range ($28.94–$30.83) and reduced his holdings by 27.8%, from 251,054 shares to 181,219 shares. The transaction is material in absolute terms ($2.1M in proceeds from a $1.3B market-cap company), yet noteworthy given the company's unprofitable status (net income of $-29,418,000.00 over the most recent fiscal year) and the stock's recent strong momentum (+61.9% over 30 days, +63.0% over 90 days). The timing of a large reduction in holdings by a senior scientific officer during a period of significant upside movement warrants investor scrutiny of underlying business conditions and future growth outlook.